SEQUANA MEDICAL N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.485 EUR | +2.41% |
|
+4.21% | -62.88% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to RED DESERT interim resul...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.45
EUR
Average target price
5.967
EUR
Spread / Average Target
+311.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -62.88% | 55.96M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- SEQUA Stock
- News Sequana Medical N.V.
- Transcript : Sequana Medical NV - Special Call